Thomas Grunwald

Head of Group "Preclinical Studies"

Fraunhofer Institute for Cell Therapy and Immunology

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

LinkedIn

Google Scholar

About

Thomas Grunwald is the Head of Group "Preclinical Studies" at the Fraunhofer Institute for Cell Therapy and Immunology in Germany. His research focuses on immunotherapy, vaccine development, and viral disease mechanisms, as demonstrated by his recent articles on SARS-CoV-2 and respiratory syncytial virus. Dr. Grunwald is particularly interested in the efficacy of neutralizing monoclonal antibodies, vector tropism, and targeted immunization strategies.

Articles (10)

Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model

Year:

2024

Influence of AAV vector tropism on long-term expression and Fc-γ receptor binding of an antibody targeting SARS-CoV-2

Year:

2024

Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias

Year:

2024

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity

Year:

2024

TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1

Year:

2024

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma

Year:

2023

Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.

Year:

2023

Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection.

Year:

2023

Immunological Quantitation of the Glycation Site Lysine-414 in Serum Albumin in Human Plasma Samples by Indirect ELISA Using Highly Specific Monoclonal Antibodies.

Year:

2023

Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.

Year:

2023

Collaborators (5)

Anke Burger-Kentischer

Head of Department

Fraunhofer Institute for Interfacial Engineering and Biotechnology

GERMANY

Ulrike Koehl

Professor and Director, Institute for Clinical Immunology

University Hospital Leipzig

GERMANY

Philip Gribbon

ITMP Head Discovery Research

Fraunhofer-Gesellschaft

GERMANY

Daniel Ramsbeck

Anhalt University of Applied Sciences

GERMANY

Ralf Hoffmann

Professor of Bioanalytics

Leipzig University

GERMANY

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI